Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer. by Maddox, P. R. et al.
Br. .1. Cancer (1992). 65, 456 460 © Macmillan Press Ltd.. 1992
Prolactin and total lactogenic hormone measured by microbioassay and
immunoassay in breast cancer
P.R. Maddox, D.L. Jones & R.E. Mansel
University Department ofSurger., L'niversity of Wales College of Medicine, Heath Park, Cardiff CF4 4XN, LK.
Sumn Basal prolactin (PRL) and total lactogenic hormone (TLH) levels were measured using a new
microbioassay (BA) and conventional immunoradiometric assay (IRMA) in patients with breast cancer and
compared to an age-matched control group. No significant differences were found using the IRMA, but BA
lactogenic levels were significantly elevated in breast cancer patients compared controls, leading to a markedly
elevated BA IRMA ratio for both PRL (2.7 vs 1.4, P<0.0001) and TLH (2.8 vs 1.4. P<O.0001) which was
greatest for postmenopausal women. Using the mean + 2 standard deviations as the upper limit of normal.
there was no significant difference between breast cancer patients and controls for IRMA. but BA and
BA IRMA PRL levels were elevated in 42% and 61% of the patients. respectively.
There was a weak negative correlation of BA and IRMA PRL with age for normals (r=- 0.53 for both)
but no correlation was evident for breast cancer patients (r = 0.06 and -0.13. respectively) implying a
sustained absolute and relative bioactive hyperprolactinaemia at all ages.
These results show increased lactogenic bioactivity in breast cancer and suggest that different forms of
bioactive prolactin undetected by IRMA (or enhancing serum factors) are present in the sera of these patients.
The pivotal role of prolactin in the development and growth
of rodent mammarv tumours is now well established, but
controversy remains on the role of the hormone in human
breast cancer. The small differences in prolactin levels in
breast cancer reported in some studies (Ohgo et al.. 1976:
Aldinger et al.. 1978: Barni et al.. 1986) and the negative
findings of others (Franks et al.. 1974: Kwa et al., 1974:
Jones et al.. 1977: Secreto et al.. 1983) may be partly
explained by failure to adequately take into account the
chronobiology of prolactin secretion. Also these conflicting
reports have used a homologous radioimmunoassay based on
the technique described by Sinha et al. (1973) to measure
serum prolactin. which may not necessarily reflect the true
biological activity of the hormone as expressed in a bioassay.
A newly developed microbioassay for lactogenic hormone
measurement was therefore used to examine prolactin and
total lactogenic bioactivity in breast disease (Maddox et al..
1989). Specificity for the measurement of prolactin bioactivity
is attained by the addition of an excess of anti-human growth
hormone antiserum to the assay culture medium.
The circulating levels of basal prolactin and growth hormone
in serum were determined both by the new microbioassav
and conventional immunoassay (using a two-site immuno-
radiometric assay) in patients with breast cancer and age-
matched controls.
Patients and methods
Patients
Basal lactogen levels were measured in 33 patients with
primary breast cancer (T4NIMO or less) and 40 age-matched
normal female volunteers. Blood samples were taken during
the luteal phase of the menstrual cycle for premenopausal
women but where the stage of the menstrual cycle could not
be calculated (e.g. irregular menstruation or post-hyster-
ectomy) subjects were analysed separately and contributed to
the total female group values. Patients with endocrinological
disorders or those taking antihypertensive drugs. tranquil-
lisers or hormones were excluded. This study was granted
ethical approval by the South Glamorgan Area Health
Authority Division of Surgery.
Blood samples were obtained between 9.00 am and 12
midday on the day before operation from patients in the
recumbent position resting in a quiet room. Serum was
separated and stored at - 20C and batch-assayed by both
immunoassav and bioassay.
Hormone materials
Human prolactin (hPRl; NlADDK-hPRL-RPI), human pro-
lactin antiserum (NIADDK-anti-hPRL-3). human growth
hormone antiserum (NIAMDD-anti-hgH-l) were obtained as
gifts from the NIAMDD NIH for use in the microbioassay.
The automated twin-site immunoradiometric assay used
human prolactin standard (Boots Celltech) calibrated against
International Reference Preparation 83 562 supplied by the
National Biological Standards Board. Prolactin antiserum
was obtained from the Scottish Antibody Prolactin Unit.
Prolactin levels were expressed as ng ml-' after standardising
to International Reference Preparation (IRP) 83 562. The
growth hormone radioimmunoassay was standardised to IRP
66 217 and serum levels were also expressed in ng ml-.
Microbioassav
Bioactive prolactin and total lactogenic hormone levels were
determined by the method previously described (Maddox et
al.. 1989). with the final values expressed as a mean of
triplicate readings in ng mlP after standardising to IRP 83
562.
Nb2 node lymphoma cells were cultured in phenol red-free
RPMI 1640 medium containing 10% horse serum. 2 g 1-'
Hepes. 2gl-l sodium bicarbonate. 100IUml-1' penicillin
and 100 ig ml-' streptomycin supplemented with 10% foetal
calf serum (FCS). The cells were transferred to culture
medium with only 1% FCS 24 h prior to a BA for PRL to
slow the rate of cell replication. After 24 h of incubation the
cells were resuspended at a concentration of 2 x 10i cells
ml-l in culture medium with no FCS. Two hundred Al of this
cell suspension was added to each of three wells for each
serum sample or prolactin standard to be tested. An excess of
anti-hGH was then added to the remaining suspended cells
(so that hGH activity was removed without affecting hPRL
concentration) and 200 Al of this cell suspension was added
to a further three wells for each sample or hPRL standard.
Samples and standards to be assayed were then added in
50 jil aliquots to six wells of a 96-well microtest plate and
incubated for 3 days at 37TC with 5% CO, and 95% humid-
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ity, after which cell mass was determined using a Titertek
Multiskan MCC 340. Serum sample unknowns were calcula-
ted from the standard curve of prolactin concentrations
against optical density as the mean of triplicate readings.
Samples without anti-hGH were used to give total lactogenic
hormone levels whilst those with anti-hGH gave values for
prolactin alone.
Immunoassav
Both assays for lactogenic hormones used a two-site immuno-
radiometric assay essentially using modification of a pre-
viously described technique (Addison & Hales. 1971). with
final values given as a mean of duplicate readings. Total
lactogenic hormone levels were calculated by the addition of
prolactin and growth hormone values. The working range of
the prolactin immunoradiometric assay was 50 to 6.500 mU
11 (1.5-197.0ngml-') with a coefficient of variation of less
than 10%. Assay sensitivity was 50 mU 1-1 (1.5 ngml-1). The
working range of the growth hormone assay was 0.5-34
mUl1' (0.25-17ngml-') with interassay and intra-assay
variation <11% and the assay sensitivity was 0.04mUl-1
(0.02 ng ml- 1).
Statistical analysis
Statistical analysis was carried out using parametric tests for
clinical data that was normally distributed (t-test) and non-
parametric statistical tests for analysis of serum levels of
lactogemnc hormones which were not normally distributed.
The upper limit of normal for BA and BA IRMA prolactin
levels was taken to be the mean + 2 standard deviations for
basal levels from age-matched control groups.
Results
The mean age (± ls.d.) of the controls was 53.8 ± 10.8 years
and 50.3 ± 10.4 years for breast cancer patients with no
significant difference between either group (Table I). The
majority of women with breast cancer were postmenopausal
as expected.
Basal lactogen levels
The basal lactogen concentrations in breast cancer patients
and controls are shown in Table II. Basal prolactin levels
determined by immunoradiometric assay (IRMA) in controls
and breast cancer patients were not significantly different. A
significantly lower IRMA growth hormone level was found
for postmenopausal breast cancer patients. leading to an
overall decrease in IRMA growth hormone in breast cancer
patients. In marked contrast. the bioassay for basal prolactin
and total lactogenic hormone levels showed significantly ele-
vated levels in breast cancer patients compared to controls
for all subjects (Figure 1). However. subgroup analysis show-
ed that although this elevation of lactogenic bioactiv%ity in
breast cancer was highly significant for postmenopausal
Table I Age ofbreast cancer patients and controls by menopausal status for basal serum
lactogen levels
Breast cancer Controls
Mean±s.d. Range n Mean±s.d. Range n
Premenopausal 42.3± 4.9 33-48 7 42.6± 5.2 35-72 16
Postmenopausal 56.9± 9.7 42-73 26 59.3 ± 7.6 49-74 18
Total 53.8± 10.8 33-73 33 50.3± 10.4 35-74 40a
n = number in each group. Student's t-test: Breast cancer *s Controls P = NS for all
subgroups and total values. aMenopausal status in six controls was indeterminable.
Table n Basal serum lactogen levels (mean± s.e.m.) by microbioassay (BA) and
immunoassay (IRMA) in breast cancer patients and controls
Prolactin Growth hormone
(ngml-') (ngml-')
n BA IRUA BA IRMA IRMA
(a) Premenopausal
Breast cancer 7 11.6±2.0 6.0±1.3 2.1±0.2 2.4±2.1
Controls 16 10.2±1.2 6.3±0.6 1.6±0.1 2.1±0.6
PI NS NS NS NS
(b) Postmenopausal
Breast cancer 26 9.6± 1.1 4.2±0.5 2.9±0.4 0.7±0.2
Controls 18 5.1±0.4 6.3±0.6 1.3±0.1 1.3±0.1
P <0.0001 NS <0.0001 <0.04
(c) Total
Breast cancer 33 10.0±1.0 4.6±0.5 2.7± 0.3 1.0±0.5
Controls 40 7.5±0.6 51+0.3 1.4+0.1 1.5+0.3
P <0.02 NS <0.0001 <0.004
Total lactogenic hormone
(ngml-'y
n BA IRMA BA IRMA
(a) Premenopausal
Breast cancer 7 17.2± 5.6 9.8±4.7 2.2±0.3
Controls 16 12.2± 1.7 8.4±0.9 1.4±0.1
P NS NS <0.005
(b) Postmenopausal
Breast cancer 26 11.5±1.2 4.9±0.5 3.0±0.4
Controls 18 6.7±0.8 5.4±0.6 1.3±0.1
P <0.0007 NS <0.0001
(c) Total
Breast cancer 33 12.7±1.5 5.9±1.1 2.8±0.3
Controls 40 9.1±0.9 6.7±0.5 1.4±0.1
P <0.009 NS <0.0001
"Mann Whitney U test: Breast cancer vs Control, NS = not significant.458 P.R. MADDOX et al.
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Figue I Basal prolactin and total lactogenic hormone levels
(mean±s.e.m.) by bioassax (BA) and immunoassay (IRMA) for
breast cancer patients and controls. Mann Whitney U test: BA vs
BA 0. P<0.2. 0. P<0.0009. RIA *s RIA P=NS.
women. the elevation in the premenopausal subgroup failed
to achieve statistical significance (Table II). Basal prolactin
levels by microbioassay (BA) were slightly elevated over
IRMA values in the control group but there was a signifi-
cantly greater elevation in patients with breast cancer.
reflected in a higher BA IRMA ratio (Figure 2) which was
significant in all subgroups except for premenopausal women.
The elevation in BA IRMA ratio was also significantly ele-
vated for total lactogenic hormone activity (Figure 3).
Elevation ofprolactin levels above upper limit ofnormal
When a cut-off of the mean + 2s.d. was used for the upper
limit of normal for prolactin values in the age-matched con-
trol groups, the number of breast cancer patients with elevat-
ed IRMA prolactin levels was of the same order as controls.
reflecting the slightly skewed distribution of normal prolactin
levels. However, basal BA prolactin levels were elevated in
18% of breast cancer patients (Table III). Relative prolactin
bioactivity was found to be the best discriminator for basal
levels with 610% of breast cancer patients having an elevated
BA IRMA prolactin ratio.
Correlation ofprolactin levels wvith age
As shown with a larger group of controls (Maddox et al..
1990), there was a weak inverse correlation of basal serum
prolactin by BA and IRMA in normal subjects with age
Table I1I Number ofbreast cancer patients and age-matched controls
with basal serum prolactin levels by bioassay (BA) and immunoassav
(IRMA) above the upper limit of normal
Number above upper limit
(percentages in parentheses)
n BAa IRVAb BA IRMA'
Breast cancer 33 6 (18) 2 (6) 20 (61)
Controls 40 2 (5) 1 (3) 0
'Upper limit of normal basal BA prolactin: 15.2 ngml-'. bUpper
limit of normal basal IRMA prolactin: 9.0 ng ml-' 'Upper limit of
normal basal BA IRMA prolactin: 2.0.
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Fire 2 Basal BA IRMA prolactin ratio for patients with
breast cancer (BC) and controls (CON) bv menopausal status.
Mann Whitney U test: BC vs CON: Total i<0.000l. Postmeno-
pausal P<0.000l. Premenopausal P = NS.
(Figure 4). However, breast cancer patients showed no cor-
relation of basal BA or IRMA prolactin with age.
Discussion
This study has shown that in accordance with the observa-
tions of several authors (Franks et al.. 1974; Sheth et al..
1975; Jones et al., 1977; Kwa et al., 1974). basal serum levels
of prolactin in patients with breast cancer are generally
within the normal range as determined by radioimmuno-
assay. Anderson et al. (1989) have reported no significant
difference in the levels of basal lactogenic hormones between
women with familial breast cancer and controls using both
the radioimmunoassay and the original Nb2 bioassay. How-
ever, the number of patients studied was smaller and the two
assays were not standardised to one reference preparation.
Also the double-antibody radioimmunoassay was used (not
the twin-site immunoradiometric assay) which may have
influenced their results (Rose et al., 1988). The present study
shows prolactin and total lactogenic hormone levels measur-
ed by microbioassay to be significantly elevated in breast
cancer patients. compared with an age-matched control
group. The majority of lactogenic activity in serum has been
shown to be due to bioactive prolactin with only a minimal
contribution from growth hormone. This finding is reflected
in a markedly elevated basal BA/IRMA ratio for prolaction
and total lactogenic hormone, with 61% of breast cancer
patients having a basal BAIIRMA prolactin ratio above the
upper limit of normal. The absolute levels of basal bioactive
prolactin in breast cancer, however, are only moderately
elevated above the normal physiological range. This may
reflect a long-term modulator control of prolactin in the
v
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breast, perhaps in concert with sex steroid hormones, leading
to the induction and promotion of breast cancer.
The predominant prolactin moiety secreted by the pituitary
is the monomer ('little' prolactin), which constitutes about
90% of total human pituitary prolactin extract; 'big' and 'big
big' prolactin comprising 10-20% and 1-8% of the total,
respectively (Garmier, 1978). There is evidence that the mono-
meric form may be more biologically active, measured by
receptor binding activity, compared to the larger forms (Gar-
nier et al., 1978; Farkouh et al., 1979). It may be that breast
cancer patients secrete more of the monomeric form of pro-
lactin, but serum factors may also play a significant role in
the expression of biological activity of prolactin in peripheral
blood.
This study has also demonstrated a moderate negative
correlation between basal serum bioactive prolactin and age
in healthy women, but no correlation was found for breast
cancer patients. This is in agreement with the findings of
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son correlation coefficient).
Rose and Pruitt (1981) who attn'buted this lack ofcorrelation
in breast cancer patients to a relative and absolute hyperpro-
lactinaemia throughout all age groups in women with breast
cancer, thereby abolishing the normal negative correlation of
prolactin within age.
Previous attempts to assess the imnportanc;e of prolactin in
breast cancer by immunoassay may have failed to measure
the biologic;ally important activity. However, whether this
elevation in basal bloactive prolactin is involved in the aetio-
logy of breast c;ancer by prolonged breast stimulation or is
itself a consequence of the neoplastic process remains uncer-
tain.
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